Its multi-targeted mechanism of action, encompassing proteasome inhibition, BCR-ABL downregulation, apoptosis, and autophagy induction, positions gambogic acid as a potentially valuable compound for further preclinical and clinical investigation in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.